Loading company
Allurion Technologies, Inc.
ALUR · OTC
$0.670.0%Sep 25 close
- 1M
- 0.0%
- 6M
- -93.3%
- 1Y
- -97.8%
ALUR · OTC
$0.670.0%Sep 25 close
The quarter ending March 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toMar 31, 2026 | 3 months toMar 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $2.9M | $5.6M | -47.19% |
| Profit | -$6.1M | -$1.5M | -306.06% |
| Profit per share | -$0.46 | -$0.31 | -48.39% |
| Free Cash Flow | -$13.3M | -$21.3M | +37.59% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Allurion Technologies, Inc. has no earnings call transcript available.
“We are pleased with our results from the fourth quarter, where we grew revenue meaningfully quarter-over-quarter for the first time in more than one year as our new commercial strategy implemented after our strategic pivot in 2025 began to take hold,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Smart Capsule, the world’s first and only swallowable, Procedureless TM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Smart Capsule is an investigational device in the United States.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Allurion Technologies, Inc.’s Item 2.02 8-K filed January 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.